Neoantigen Targeted Therapies Market Size, Share, And Trends - Global Forecast 2026-2032 AI And Personalized Cancer Vaccines Drive 16.66% CAGR To USD 15.61 Billion


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Boost ROI through AI-led discovery, combination trials, scalable manufacturing, strategic partnerships, and outcomes-based, diagnostic-linked reimbursement.

Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Neoantigen Targeted Therapies Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global neoantigen targeted therapies market research report provides strategic analysis of a rapidly advancing precision oncology sector. Valued at an estimated USD 6.15 billion in 2026, the market is projected to reach USD 15.61 billion by 2032, expanding at a compound annual growth rate of 16.66%.

Market Overview

Neoantigen targeted therapies focus on tumor-specific mutations generally absent from healthy tissue. These targets support personalized cancer vaccines, adoptive T-cell therapies, T-cell receptor programs, and combination regimens designed to direct immune activity toward patient-specific or shared tumor antigens.

Next-generation sequencing, HLA typing, immunopeptidomics, and advanced bioinformatics are improving the speed and reliability of neoantigen identification. Although clinical development remains complex, the potential for greater tumor specificity, immune memory, and differentiation from conventional treatments continues to drive investment.

Transformative Market Shifts

The sector is progressing from exploratory immuno-oncology research toward scalable translational platforms. Whole-exome sequencing, RNA sequencing, single-cell analysis, and tumor microenvironment profiling are enabling developers to select clinically relevant epitopes and design personalized therapies within commercially viable timelines.

Development strategies are also shifting toward rational combinations involving checkpoint inhibitors, cytokine modulation, lymphodepletion, and tumor microenvironment interventions. The analysis supports strategic planning by highlighting how antigen presentation, T-cell fitness, immune infiltration, and resistance management influence durable clinical response.

Artificial Intelligence in Neoantigen Discovery

Artificial intelligence is becoming central to discovery, prioritization, and manufacturing design. AI-enabled platforms can integrate tumor DNA and RNA sequencing, HLA binding predictions, clonality, antigen processing signals, and immunogenicity models to reduce low-value candidates entering costly validation workflows.

Predictive analytics also supports patient selection, trial stratification, toxicity monitoring, and adaptive protocol design. These insights allow decision-makers to assess emerging platform capabilities and identify opportunities for differentiated clinical development.

Regional Market Insights

  • North America: Leads through its concentration of biotechnology companies, academic cancer centers, financing, sequencing adoption, and regulated clinical trial activity.
  • Europe: Benefits from established biopharmaceutical infrastructure, strong oncology research systems, and coordinated regulatory pathways, although reimbursement and manufacturing capacity vary.
  • Asia-Pacific: China, Japan, South Korea, Australia, India, and ASEAN markets are expanding precision medicine, cancer genomics, and cell therapy capabilities.
  • Latin America: Brazil and Mexico offer growing oncology demand and clinical research potential, while access to advanced diagnostics remains uneven.
  • Middle East and Africa: GCC investment in genomics and specialty oncology is creating opportunities, while African adoption depends on infrastructure, partnerships, and equitable access models.

Innovation Blocs and Country Opportunities

G7 countries retain a strong position through advanced research funding, regulatory experience, and clinical capacity. The European Union supports multi-country development through harmonized pathways and research networks, while BRICS economies offer large patient populations and expanding sequencing and biomanufacturing capabilities.

The United States leads commercialization potential, while the United Kingdom, Germany, and France remain prominent European development centers. China is a major force in genomics and cell therapy; Japan and South Korea offer sophisticated regulatory and manufacturing systems; India provides scale and cost-efficient research; and Australia is a preferred early-phase oncology trial destination. Country-level comparisons can inform market entry priorities and help mitigate regulatory, operational, and access risks.

Strategic Priorities for Industry Leaders

  • Integrate tumor sequencing, HLA typing, transcriptomics, immunopeptidomics, and validated AI models.
  • Develop combination strategies early, particularly with checkpoint inhibitors and tumor microenvironment modulators.
  • Build partnerships with sequencing providers, cancer centers, CDMOs, and real-world data networks.
  • Plan payer evidence, manufacturing cost controls, sample logistics, and region-specific access models before pivotal trials.
  • Evaluate outcomes-based reimbursement and diagnostic-linked value demonstration.

Key Takeaways from This Report

  • The market is forecast to grow from USD 6.15 billion in 2026 to USD 15.61 billion by 2032.
  • AI, advanced sequencing, and immunopeptidomics are accelerating neoantigen discovery and prioritization.
  • Combination therapies and scalable personalized manufacturing are becoming central competitive factors.
  • North America leads, while Europe and Asia-Pacific present significant development and commercialization opportunities.
  • Clinical evidence, biomarker strategy, manufacturing speed, and regional access planning will shape long-term market leadership.

Key Attributes:

Report Attribute Details
No. of Pages 188
Forecast Period 2026 - 2032
Estimated Market Value (USD) in 2026 $6.15 Billion
Forecasted Market Value (USD) by 2032 $15.61 Billion
Compound Annual Growth Rate 16.6%
Regions Covered Global


Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Neoantigen Targeted Therapies Market, by Therapy Modality
7.1. Introduction
7.2. Adoptive Cell Therapy
7.2.1. CAR-T Cell Therapy
7.2.2. T Cell Receptor (TCR) Therapy
7.2.3. Tumor-infiltrating lymphocytes (TIL)
7.3. Personalized Neoantigen Vaccines
7.3.1. Dendritic Cell (DC) Vaccines
7.3.2. DNA/ RNA-based Vaccines
7.3.3. Peptide (SLP) Vaccines
8. Neoantigen Targeted Therapies Market, by Treatment Approach
8.1. Introduction
8.2. Combination Therapy
8.3. Monotherapy
9. Neoantigen Targeted Therapies Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.3.3. Subcutaneous
10. Neoantigen Targeted Therapies Market, by Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Neoantigen Targeted Therapies Market, by Target Disease Indication
11.1. Introduction
11.2. Bone Cancer
11.3. Colorectal Cancer
11.4. Gynecological Cancer
11.5. Non-Small Cell Lung Cancer
11.6. Renal Cell Carcinoma
12. Neoantigen Targeted Therapies Market, by End-User
12.1. Introduction
12.2. Academic & Government Research Institutes
12.3. Hospitals & Clinics
12.4. Specialty Clinics
13. Neoantigen Targeted Therapies Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Neoantigen Targeted Therapies Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Neoantigen Targeted Therapies Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. Germany
15.5. United Kingdom
15.6. India
15.7. Japan
15.8. Russia
15.9. Brazil
15.10. Canada
15.11. Italy
15.12. Mexico
15.13. France
15.14. Spain
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Achilles Therapeutics Limited
17.2. Agenus Inc.
17.3. AstraZeneca plc
17.4. BioNTech SE
17.5. Bristol-Myers Squibb Company
17.6. CureVac N.V.
17.7. Eli Lilly and Company
17.8. EpiVax, Inc.
17.9. F. Hoffmann-La Roche AG
17.10. Genentech, Inc.
17.11. Genocea Biosciences, Inc.
17.12. Gilead Sciences, Inc.
17.13. GlaxoSmithKline plc
17.14. Gritstone bio, Inc.
17.15. Immatics N.V.
17.16. Immunomic Therapeutics, Inc.
17.17. IOVANCE Biotherapeutics, Inc.
17.18. Medigene AG
17.19. Merck & Co., Inc.
17.20. Moderna, Inc.
17.21. Neon Therapeutics, Inc.
17.22. Nykode Therapeutics
17.23. Pfizer Inc.
17.24. Precision Biologics
17.25. Valo Therapeutics Ltd
18. Key Experts

List of Figures [23]
List of Tables [323]
For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112026004107003653ID1111990333


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search